---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-104106"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-09-01T11:01:13+00:00"
generated_at: "2026-09-01T11:05:11.673842+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# BioXcel enters Chapter 11, secures $77.25M DIP, Nasdaq delisting on Sept 8

## Summary
- DIP facility up to $77.25M from Oaktree and Qatar Investment Authority; 13% interest, matures Jan 27, 2027.
- New money loans $19M in two $9.5M draws; roll-up loans $58.25M converting prepetition debt dollar-for-dollar.
- Nasdaq to delist BTAI due to Chapter 11; trading suspended Sept 8, 2026; stock to move to pink sheets.
- Company not appealing delisting; expects $9.5M initial draw and $29.75M roll-up on Sept 1, 2026.
- Exit fee 4% on loans; default interest 2% above applicable rate; DIP secured by superpriority liens.

## SEC filing metadata
- accession: 0001104659-26-104106
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-09-01T11:01:13+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.03, 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926104106/0001104659-26-104106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926104106/tm2624539d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-104106
- JSON: https://secwatch.observer/filing/0001104659-26-104106.json
- Plain text: https://secwatch.observer/filing/0001104659-26-104106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.